Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis

Review (14 phase III RCTs) reported survival benefit with atezolizumab and bevacizumab in first-line setting vs lenvatinib (HR, 0.63; 95% CI, 0.44-0.89), sorafenib (0.58), and nivolumab (0.68); and with regorafenib (0.62) and cabozantinib (0.62) in refractory setting, vs placebo.

JAMA Oncology